Results 51 to 60 of about 20,710 (242)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence [PDF]

open access: yesThe Korean Journal of Internal Medicine, 2020
Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF.
Hong-Mi Choi, Mi-Seung Shin
doaj   +1 more source

Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena

open access: yesJournal of Diabetes, 2023
AbstractNeprilysin (NEP) is a transmembrane zinc‐dependent metalloproteinase that inactivates various peptide hormones including glucagon‐like peptide 1 (GLP‐1). NEP inhibitors may be effective in the management of type 2 diabetes mellitus (T2DM) by increasing the circulating level of GLP‐1.
Faisal Holil AlAnazi   +8 more
openaire   +2 more sources

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor   +8 more
wiley   +1 more source

Toward Stability Enhancement of NTS1R-Targeted Radioligands: Structural Interventions on [99mTc]Tc-DT1

open access: yesPharmaceutics, 2023
The neurotensin subtype 1 receptor (NTS1R) is overexpressed in a number of human tumors, thereby representing a valid target for cancer theranostics with radiolabeled neurotensin (NT) analogs like [99mTc]Tc-DT1 (DT1, N4-Gly7-NT(8-13)). Thus far, the fast
Panagiotis Kanellopoulos   +3 more
doaj   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen   +4 more
wiley   +1 more source

Not so Dangerous After All? Venom Composition and Potency of the Pholcid (Daddy Long-Leg) Spider Physocyclus mexicanus

open access: yesFrontiers in Ecology and Evolution, 2019
Pholcid spiders (Araneae: Pholcidae), officially “cellar spiders” but popularly known as “daddy long-legs,” are renown for the potential of deadly toxic venom, even though venom composition and potency has never formally been studied.
Pamela A. Zobel-Thropp   +6 more
doaj   +1 more source

Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer’s Mice

open access: yesPharmaceuticals, 2021
Angiotensin receptor blockers (ARBs) have demonstrated multiple neuroprotective benefits in Alzheimer’s disease (AD) models. However, their beneficial effects on memory deficits, cholinergic activity, neurogenesis and Amyloid beta (Aβ) clearance reveal ...
Henning Johannes Drews   +13 more
doaj   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya   +9 more
wiley   +1 more source

High resolution crystal structure of substrate-free human neprilysin [PDF]

open access: yes, 2018
Neprilysin is a transmembrane M13 zinc metalloprotease responsible for the degradation of several biologically active peptides including insulin, enkephalin, substance P, bradykinin, endothelin-1, neurotensin and amyloid-β.
K. Ravi Acharya   +5 more
core   +1 more source

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundOur aim was to evaluate the association between the soluble form of neprilysin (sNEP) levels and long‐term all‐cause, cardiovascular, and acute heart failure (AHF) recurrent admissions in an ambulatory cohort of patients with heart failure ...
Julio Núñez   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy